Forget the sleepy chart—this is a news-driven rocket! 🚀 Plogosertib data is legit exciting, but the real story is that reverse split and private placements. They're fixing the balance sheet to survive. The pop to $1.26 on decent volume shows smart money is listening. This is a high-risk punt on a turnaround, but the narrative just got a lot more interesting. Speculative BUY. #BiotechBet

"Boom! Cyclacel’s liver cancer data is sending this stock into orbit 🚀—paired with a stock split and Nasdaq compliance, it’s a triple espresso of bullish news. The 9-period WMA just punched above the 21, RSI is warming up (57 = room to run), and volume? Explosive. Chart’s a rollercoaster, but that midday spike to $18 screams FOMO fuel. BUY the hype (but maybe pack a parachute). #BiotechBoom"

"Boom! Cyclacel’s preclinical liver cancer data lit a rocket under this stock 🚀—from $3 to $17 in days! The 9-period WMA just punched through the 21 like it’s nothing, and RSI at 59 says there’s room to run. Volume? Explosive. Chart’s a wild rollercoaster, but that news is *real* momentum. Only caution: that wild 50% intraday dip screams volatility. Still, with Nasdaq compliance back and fresh cash in the tank? BUY the hype (but buckle up!). #BiotechBoom"

"Boom! Cyclacel’s liver cancer data is the spark this rocket needed 🚀—stock splits, fresh funding, and Nasdaq compliance? Bullish vibes. RSI jumped from oversold to ‘just warming up,’ and that 30M volume spike screams conviction. Chart’s a wild ride (hello, 18.34 high!), but the 9-day WMA just yeeted past the 21-day. BUY the momentum—biotech chaos is where fortunes are made. #DiamondInTheRough"